Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The combination of oxaliplatin, 5-FU, leucovorin, and capecitabine is hypothesized to retain and potentially improve upon the activity of the FOLFOX regimens. Additionally, the use of an oral rather than an infusional 5-fu regimen represents a clear advantage in terms of both patient convenience and lack of associated catheter-related complications.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Treatments: Capecitabine; Leucovorin; Oxaliplatin

Criteria

Inclusion Criteria:

• no prior treatment for metastatic disease

• PS 0-2

• measurable disease

Exclusion Criteria:

• neuropathy > or equal to grade 2

• concomitant radiation therapy or other systemic cancer therapies

• brain mets